View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

NSF Launches Further Qualified Person Training in 2019

What does the future hold for the qualified person (QP) post-Brexit? There has been much debate on this matter. We do know that all EU centralised marketing authorisations must be held by a legal entity within the EU and that QP certification and pharmacovigilance (PV) need to occur in the EU.

The role of the QP is already in UK law (SI 2012-1916) and the UK is expected to retain the role of the QP post-Brexit.  It does mean, however, that EU QPs may no longer be able to accept certification by UK QPs and vice-versa. The result of all of this is that there will be a growing need for more QPs both in the UK and in the EU.

NSF has been running QP training courses for 28 years.  With 177 training modules, more than 4,000 delegates and a pass rate of 96%, the company has just seen its 300th QP pass their viva! Congratulations global technical director and QP of health supply at Reckitt Benckiser Healthcare UK Alan Clark.

NSF currently runs 12 modules, meeting the requirements of the UK QP Study Guide, over a 21-month period.  With the demand for this training increasing and delegates attending from overseas as well as the EU, additional courses will be launched from January 2019 in both London and Brighton. This will provide the opportunity for all 12 modules to be completed over a 12-month period, providing flexibility and choice of location to the delegate.

In June and September 2018, NSF ran a seminar in each of its new locations, which were well attended, and it received some great feedback on the new venues.  Topics covered were a pharmaceutical law and Brexit update, as well as an overview of document simplification methods and techniques.  There were plenty of discussions on the challenges that industry faces, with deviations and corrective and preventative actions (CAPA), serialisation, PV, data integrity and Annex 1 as some of the continuing topics named.

Each module is a stand-alone course and can be taken in any order. For those taking all modules, there will still be the opportunity to gain postgraduate qualifications from the University of Strathclyde.

The teaching and learning on the courses is highly interactive, using a combination of lectures, discussion scenarios and teamwork, which provide a context to help with decision-making, a prerequisite for the future QP. There are also additional site visits planned to pharmaceutical manufacturing facilities in the UK to see the real-life application of what has been learned.

Our next QP courses include:

  • Pharmaceutical Packaging – 14 January to 17 January in Hatfield, UK
  • Pharmaceutical Formulation and Processing – Part 1 – 28 January to 1 February in York, UK
  • Pharmaceutical Formulation and Processing – Part 2 – 11 March to 15 March in York, UK
  • Pharmaceutical Quality Systems – 8 April to 11 April in London, UK

Making a case for good manufacturing practice (GMP) certification of an excipient manufacturer should be a straightforward exercise since the benefits appear so clear cut...
Risk management across a global supply chain has never been a stronger factor in assuring economic success than it is now.
NSF Pharma Biotech's CEO Martin Lush recently had a meeting with a CEO to help solve his company’s pain points.
The heart of the European Union (EU) regulation of in vitro diagnostic medical devices (IVDs) lies in allowing market access to IVDs that offer clinical...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology